<div id="readability-page-1"><p>ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) shares hit a new 52-week high during trading on Saturday . The company traded as high as $25.23 and last traded at $22.26, with a volume of 17783924 shares changing hands. The stock had previously closed at $17.60.</p><div><p><span></span><span>Get <strong>ACADIA Pharmaceuticals</strong> alerts:</span></p></div><h2>Analysts Set New Price Targets</h2><ul><li>Acadia Pharmaceuticals: A Mid-Cap Biotech Making Large Moves</li></ul><p>A number of analysts have commented on ACAD shares. Cantor Fitzgerald  reaffirmed an &#34;overweight&#34; rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. HC Wainwright  reissued a &#34;buy&#34; rating and set a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft started coverage on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They set a &#34;hold&#34; rating and a $22.00 price objective on the stock. UBS Group cut their price objective on shares of ACADIA Pharmaceuticals from $25.00 to $22.00 and set a &#34;buy&#34; rating on the stock in a research report on Monday, April 28th. Finally, StockNews.com cut shares of ACADIA Pharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Monday, May 12th. Five analysts have rated the stock with a hold rating and seven have assigned  a buy rating to the stock. According to data from MarketBeat, the stock  has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $24.70.</p><p><b>View Our Latest Report on ACAD</b></p><h2>ACADIA Pharmaceuticals Stock Performance</h2><p>The company has a market cap of $3.72 billion, a price-to-earnings ratio of 28.54 and a beta of 0.47. The stock's fifty day moving average is $15.91 and its two-hundred day moving average is $17.07. </p><p>ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.10 by $0.01. The firm had revenue of $244.32 million during the quarter, compared to analyst estimates of $239.32 million. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The company's revenue for the quarter was up 18.7% on a year-over-year basis. During the same quarter last year, the business posted $0.10 EPS.  On average, equities research analysts expect that  ACADIA Pharmaceuticals Inc. will post 0.7 EPS for the current year. </p><h2>Insider Buying and Selling at ACADIA Pharmaceuticals</h2><p>In other news, EVP Mark C. Schneyer sold 3,498 shares of the firm's stock in a transaction that occurred on Friday, May 2nd. The shares were sold at an average price of $14.60, for a total transaction of $51,070.80. Following the completion of the sale, the executive vice president now owns 62,773 shares in the company, valued at $916,485.80. This trade represents a 5.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Elizabeth A. Garofalo sold 4,919 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total transaction of $89,673.37. Following the sale, the director now owns 17,595 shares of the company's stock, valued at approximately $320,756.85. The trade was a 21.85% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 18,994 shares of company stock worth $313,131. Insiders own  26.50% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Hedge funds have recently bought and sold shares of the business. Assenagon Asset Management S.A. bought a new position in  ACADIA Pharmaceuticals in the 1st quarter valued at $60,845,000.  Point72 Asset Management L.P. bought a new position in  ACADIA Pharmaceuticals in the 4th quarter valued at $40,935,000.  SG Americas Securities LLC boosted its holdings in  ACADIA Pharmaceuticals by 380.3% in the 4th quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company's stock valued at $45,576,000 after purchasing an additional 1,966,607 shares during the period.  American Century Companies Inc. boosted its holdings in  ACADIA Pharmaceuticals by 1,055.8% in the 1st quarter. American Century Companies Inc. now owns 1,632,749 shares of the biopharmaceutical company's stock valued at $27,120,000 after purchasing an additional 1,491,484 shares during the period.  Finally, Norges Bank bought a new position in  ACADIA Pharmaceuticals in the 4th quarter valued at $25,555,000. 96.71% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>About ACADIA Pharmaceuticals</h2> (Get Free Report)<p>ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than ACADIA Pharmaceuticals</li><li>What is the FTSE 100 index? </li><li>Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision</li><li>There Are Different Types of Stock To Invest In</li><li>Retail Investors Are Betting Big on Rocket Lab—Should You Too?</li><li>Uptrend Stocks Explained: Learn How to Trade Using Uptrends</li><li>GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in ACADIA Pharmaceuticals Right Now?</h2><p>Before you consider ACADIA Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ACADIA Pharmaceuticals wasn't on the list.</p><p>While ACADIA Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ACAD

<p>ACADIA Pharmaceuticals (NASDAQ:ACAD) shares reached a new 52-week high of $25.23, closing at $22.26 with significant trading volume. Analysts have mixed ratings, with Cantor Fitzgerald and HC Wainwright setting price targets of $28.00 and $27.00, respectively. The company reported a quarterly EPS of $0.11, exceeding estimates, and a revenue increase of 18.7% year-over-year. Insider trading activity includes sales by executives, while hedge funds have increased their positions significantly. The stock has a consensus rating of "Moderate Buy" with a target price of $24.70.</p>

ACADIA Pharmaceuticals (NASDAQ:ACAD) Reaches New 12-Month High - Time to Buy?